Approval · Notice of Compliance 34857 · 2025
JAMP-MEMANTINE: Notice of Compliance 34857
Issued February 18, 2025
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 34857
- Date
- February 18, 2025
- Company
- JAMP Pharma CorporationBoucherville, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to an Abbreviated New Drug Submission (SANDS), supplement
- Submission class
- Other
- Reason
- Addition of a manufacturing site and/or manufacturer involving production of the starting material. Replacement of a manufacturing site and/or manufacturer involving production of the intermediate. Change in the specification for the drug substance.
- Canadian reference product
- EBIXA (Lundbeck Canada Inc)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| JAMP-MEMANTINE | Not yet assigned | — |
Medicinal ingredients
- MEMANTINE HYDROCHLORIDE 5 MG per TAB
- MEMANTINE HYDROCHLORIDE 10 MG per TAB